Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Altered cell-cycle control, inflammation and adhesion in high-risk persistent bronchial dysplasia.

Merrick DT, Edwards MG, Franklin WA, Sugita M, Keith RL, Miller YE, Friedman MB, Dwyer-Nield LD, Tennis MA, O'Keefe MC, Donald EJ, Malloy JM, van Bokhoven A, Wilson S, Koch PJ, O'Shea C, Coldren C, Orlicky DJ, Lu X, Baron AE, Hickey G, Kennedy TC, Powell R, Heasley L, Bunn PA, Geraci M, Nemenoff RA.

Cancer Res. 2018 Jul 11. pii: canres.3822.2017. doi: 10.1158/0008-5472.CAN-17-3822. [Epub ahead of print]

PMID:
29997230
2.

Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II.

Li HY, McSharry M, Walker D, Johnson A, Kwak J, Bullock B, Neuwelt A, Poczobutt JM, Sippel TR, Keith RL, Weiser-Evans MCM, Clambey E, Nemenoff RA.

Oncoimmunology. 2018 Feb 13;7(5):e1423182. doi: 10.1080/2162402X.2017.1423182. eCollection 2018.

PMID:
29721380
3.

Exhaustion of Airway Basal Progenitor Cells in Early and Established Chronic Obstructive Pulmonary Disease.

Ghosh M, Miller YE, Nakachi I, Kwon JB, Barón AE, Brantley AE, Merrick DT, Franklin WA, Keith RL, Vandivier RW.

Am J Respir Crit Care Med. 2018 Apr 1;197(7):885-896. doi: 10.1164/rccm.201704-0667OC.

PMID:
29211494
4.

The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model.

Dwyer-Nield L, Hickey GA, Friedman M, Choo K, McArthur DG, Tennis MA, New ML, Geraci M, Keith RL.

Cancer Prev Res (Phila). 2017 Nov;10(11):671-679. doi: 10.1158/1940-6207.CAPR-17-0050. Epub 2017 Aug 29.

PMID:
28851689
5.

Prostacyclin reverses the cigarette smoke-induced decrease in pulmonary Frizzled 9 expression through miR-31.

Tennis MA, New ML, McArthur DG, Merrick DT, Dwyer-Nield LD, Keith RL.

Sci Rep. 2016 Jun 24;6:28519. doi: 10.1038/srep28519.

6.

Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.

Merrick DT, Gao D, Miller YE, Keith RL, Baron AE, Feser W, Kennedy TC, Blatchford PJ, Braudrick S, Hirsch FR, Heasley L, Bunn PA Jr, Franklin WA.

Cancer Prev Res (Phila). 2016 Jan;9(1):96-104. doi: 10.1158/1940-6207.CAPR-15-0305. Epub 2015 Nov 5.

7.

Tracheal dysplasia precedes bronchial dysplasia in mouse model of N-nitroso trischloroethylurea induced squamous cell lung cancer.

Ghosh M, Dwyer-Nield LD, Kwon JB, Barthel L, Janssen WJ, Merrick DT, Keith RL.

PLoS One. 2015 Apr 10;10(4):e0122823. doi: 10.1371/journal.pone.0122823. eCollection 2015.

8.

Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions.

Nakachi I, Rice JL, Coldren CD, Edwards MG, Stearman RS, Glidewell SC, Varella-Garcia M, Franklin WA, Keith RL, Lewis MT, Gao B, Merrick DT, Miller YE, Geraci MW.

Cancer Prev Res (Phila). 2014 Feb;7(2):255-65. doi: 10.1158/1940-6207.CAPR-12-0485. Epub 2013 Dec 17.

9.

Lung cancer chemoprevention: current status and future prospects.

Keith RL, Miller YE.

Nat Rev Clin Oncol. 2013 Jun;10(6):334-43. doi: 10.1038/nrclinonc.2013.64. Epub 2013 May 21. Review.

10.

Chemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Szabo E, Mao JT, Lam S, Reid ME, Keith RL.

Chest. 2013 May;143(5 Suppl):e40S-e60S. doi: 10.1378/chest.12-2348. Review.

11.

Endobronchial miRNAs as biomarkers in lung cancer chemoprevention.

Mascaux C, Feser WJ, Lewis MT, Barón AE, Coldren CD, Merrick DT, Kennedy TC, Eckelberger JI, Rozeboom LM, Franklin WA, Minna JD, Bunn PA, Miller YE, Keith RL, Hirsch FR.

Cancer Prev Res (Phila). 2013 Feb;6(2):100-8. doi: 10.1158/1940-6207.CAPR-12-0382. Epub 2012 Dec 26.

12.

Lung cancer chemoprevention.

Keith RL.

Proc Am Thorac Soc. 2012 May;9(2):52-6. doi: 10.1513/pats.201107-038MS.

13.

Con: the case for expanded lung cancer research support.

Geraci MW, Keith RL.

Am J Respir Crit Care Med. 2011 Dec 1;184(11):1234-6. doi: 10.1164/rccm.201104-0697ED. No abstract available.

14.

N-nitroso-tris-chloroethylurea induces premalignant squamous dysplasia in mice.

Hudish TM, Opincariu LI, Mozer AB, Johnson MS, Cleaver TG, Malkoski SP, Merrick DT, Keith RL.

Cancer Prev Res (Phila). 2012 Feb;5(2):283-9. doi: 10.1158/1940-6207.CAPR-11-0257. Epub 2011 Nov 15.

15.

Oral iloprost improves endobronchial dysplasia in former smokers.

Keith RL, Blatchford PJ, Kittelson J, Minna JD, Kelly K, Massion PP, Franklin WA, Mao J, Wilson DO, Merrick DT, Hirsch FR, Kennedy TC, Bunn PA Jr, Geraci MW, Miller YE.

Cancer Prev Res (Phila). 2011 Jun;4(6):793-802. doi: 10.1158/1940-6207.CAPR-11-0057.

16.

The detection of chromosomal aneusomy by fluorescence in situ hybridization in sputum predicts lung cancer incidence.

Varella-Garcia M, Schulte AP, Wolf HJ, Feser WJ, Zeng C, Braudrick S, Yin X, Hirsch FR, Kennedy TC, Keith RL, Barón AE, Belinsky SA, Miller YE, Byers T, Franklin WA.

Cancer Prev Res (Phila). 2010 Apr;3(4):447-53. doi: 10.1158/1940-6207.CAPR-09-0165. Epub 2010 Mar 23.

17.

Prostacyclin inhibits non-small cell lung cancer growth by a frizzled 9-dependent pathway that is blocked by secreted frizzled-related protein 1.

Tennis MA, Van Scoyk M, Heasley LE, Vandervest K, Weiser-Evans M, Freeman S, Keith RL, Simpson P, Nemenoff RA, Winn RA.

Neoplasia. 2010 Mar;12(3):244-53.

18.

The role of prostacyclin in lung cancer.

Tennis MA, Vanscoyk M, Keith RL, Winn RA.

Transl Res. 2010 Feb;155(2):57-61. doi: 10.1016/j.trsl.2009.06.010. Epub 2009 Jul 23.

PMID:
20129485
19.

Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.

Keith RL, Karoor V, Mozer AB, Hudish TM, Le M, Miller YE.

Lung Cancer. 2010 Oct;70(1):37-42. doi: 10.1016/j.lungcan.2010.01.004. Epub 2010 Jan 29.

20.

A randomized phase II chemoprevention trial of 13-CIS retinoic acid with or without alpha tocopherol or observation in subjects at high risk for lung cancer.

Kelly K, Kittelson J, Franklin WA, Kennedy TC, Klein CE, Keith RL, Dempsey EC, Lewis M, Jackson MK, Hirsch FR, Bunn PA, Miller YE.

Cancer Prev Res (Phila). 2009 May;2(5):440-9. doi: 10.1158/1940-6207.CAPR-08-0136. Epub 2009 Apr 28.

21.

Chemoprevention of lung cancer.

Keith RL.

Proc Am Thorac Soc. 2009 Apr 15;6(2):187-93. doi: 10.1513/pats.200807-067LC. Review.

22.

Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA.

Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, Keith RL, Boé DM, Morimoto K, Bowler RP, Day BJ, Janssen WJ, Henson PM, Vandivier RW.

Am J Respir Crit Care Med. 2009 Jun 1;179(11):1011-21. doi: 10.1164/rccm.200807-1148OC. Epub 2009 Mar 5.

23.

Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma.

Nemenoff R, Meyer AM, Hudish TM, Mozer AB, Snee A, Narumiya S, Stearman RS, Winn RA, Weiser-Evans M, Geraci MW, Keith RL.

Cancer Prev Res (Phila). 2008 Oct;1(5):349-56. doi: 10.1158/1940-6207.CAPR-08-0145.

24.

Detection and localization of intraepithelial neoplasia and invasive carcinoma using fluorescence-reflectance bronchoscopy: an international, multicenter clinical trial.

Edell E, Lam S, Pass H, Miller YE, Sutedja T, Kennedy T, Loewen G, Keith RL, Gazdar A.

J Thorac Oncol. 2009 Jan;4(1):49-54. doi: 10.1097/JTO.0b013e3181914506. Erratum in: J Thorac Oncol. 2009 Apr;4(4):558. Gazdar, Adi [added].

25.

Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease.

Miller YE, Blatchford P, Hyun DS, Keith RL, Kennedy TC, Wolf H, Byers T, Bunn PA Jr, Lewis MT, Franklin WA, Hirsch FR, Kittelson J.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2425-31.

26.

Chromosomal aneusomy in bronchial high-grade lesions is associated with invasive lung cancer.

Jonsson S, Varella-Garcia M, Miller YE, Wolf HJ, Byers T, Braudrick S, Kiatsimkul P, Lewis M, Kennedy TC, Keith RL, Bjornsson J, McWilliams A, Lam S, Hirsch FR, Franklin WA.

Am J Respir Crit Care Med. 2008 Feb 1;177(3):342-7. Epub 2007 Nov 7.

27.

Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition).

Jett JR, Schild SE, Keith RL, Kesler KA; American College of Chest Physicians.

Chest. 2007 Sep;132(3 Suppl):266S-276S.

PMID:
17873173
28.

Prostacyclin in lung cancer.

Keith RL, Geraci MW.

J Thorac Oncol. 2006 Jul;1(6):503-5. Review. No abstract available.

29.

Lack of association between sputum atypia and chronic obstructive pulmonary disease mortality.

Miller YE, Vu KO, Kennedy TC, Hirsch FR, Petty TL, Bunn PA Jr, Keith RL, Franklin WA, Wolf HJ, Prindiville S, Byers T.

J Thorac Oncol. 2006 May;1(4):302-7.

30.

Inhaled corticosteroids and lung cancer chemoprevention.

Miller YE, Keith RL.

Am J Respir Crit Care Med. 2007 Apr 1;175(7):636-7. No abstract available.

PMID:
17384324
31.

Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke.

Nana-Sinkam SP, Lee JD, Sotto-Santiago S, Stearman RS, Keith RL, Choudhury Q, Cool C, Parr J, Moore MD, Bull TM, Voelkel NF, Geraci MW.

Am J Respir Crit Care Med. 2007 Apr 1;175(7):676-85. Epub 2007 Jan 25.

32.

Prostaglandin E2 receptor subtype 2 (EP2) null mice are protected against murine lung tumorigenesis.

Keith RL, Geraci MW, Nana-Sinkam SP, Breyer RM, Hudish TM, Meyer AM, Malkinson AM, Dwyer-Nield LD.

Anticancer Res. 2006 Jul-Aug;26(4B):2857-61.

33.

Amiodarone-induced alveolar hemorrhage.

Iskandar SB, Abi-Saleh B, Keith RL, Byrd RP Jr, Roy TM.

South Med J. 2006 Apr;99(4):383-7.

PMID:
16634249
34.

Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer.

Merrick DT, Kittelson J, Winterhalder R, Kotantoulas G, Ingeberg S, Keith RL, Kennedy TC, Miller YE, Franklin WA, Hirsch FR.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2281-8.

35.

Attenuation of the pulmonary inflammatory response following butylated hydroxytoluene treatment of cytosolic phospholipase A2 null mice.

Meyer AM, Dwyer-Nield LD, Hurteau G, Keith RL, Ouyang Y, Freed BM, Kisley LR, Geraci MW, Bonventre JV, Nemenoff RA, Malkinson AM.

Am J Physiol Lung Cell Mol Physiol. 2006 Jun;290(6):L1260-6. Epub 2006 Jan 27.

36.

Septic pulmonary emboli due to periodontal disease.

Mattar CS, Keith RL, Byrd RP Jr, Roy TM.

Respir Med. 2006 Aug;100(8):1470-4. Epub 2006 Jan 11. Review.

37.

Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model.

Stearman RS, Dwyer-Nield L, Zerbe L, Blaine SA, Chan Z, Bunn PA Jr, Johnson GL, Hirsch FR, Merrick DT, Franklin WA, Baron AE, Keith RL, Nemenoff RA, Malkinson AM, Geraci MW.

Am J Pathol. 2005 Dec;167(6):1763-75.

38.

High prevalence of occult endobronchial malignancy in high risk patients with moderate sputum atypia.

Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA Jr, Miller YE.

Lung Cancer. 2005 Aug;49(2):187-91. Epub 2005 Apr 14.

PMID:
16022912
39.

Lung cancer: genetics of risk and advances in chemoprevention.

Keith RL, Miller YE.

Curr Opin Pulm Med. 2005 Jul;11(4):265-71. Review.

PMID:
15928489
40.

Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis.

Merrick DT, Haney J, Petrunich S, Sugita M, Miller YE, Keith RL, Kennedy TC, Franklin WA.

Lung Cancer. 2005 Apr;48(1):31-45.

PMID:
15777969
41.

Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer.

Varella-Garcia M, Kittelson J, Schulte AP, Vu KO, Wolf HJ, Zeng C, Hirsch FR, Byers T, Kennedy T, Miller YE, Keith RL, Franklin WA.

Cancer Detect Prev. 2004;28(4):244-51.

PMID:
15350627
42.

Pulmonary prostacyclin synthase overexpression chemoprevents tobacco smoke lung carcinogenesis in mice.

Keith RL, Miller YE, Hudish TM, Girod CE, Sotto-Santiago S, Franklin WA, Nemenoff RA, March TH, Nana-Sinkam SP, Geraci MW.

Cancer Res. 2004 Aug 15;64(16):5897-904.

43.

Prostacyclin in human non-small cell lung cancers.

Nana-Sinkam P, Golpon H, Keith RL, Oyer RJ, Sotto-Santiago S, Moore MD, Franklin W, Nemenoff RA, Geraci MW.

Chest. 2004 May;125(5 Suppl):141S. No abstract available.

PMID:
15136467
44.

High prevalence of endobronchial malignancy in high-risk patients with moderate dysplasia in sputum.

Kennedy TC, Franklin WA, Prindiville SA, Cook R, Dempsey EC, Keith RL, Hirsch FR, Merrick TA, Shroyer KR, Petty TL, Byers T, Bunn PA Jr, Miller YE.

Chest. 2004 May;125(5 Suppl):109S. No abstract available.

PMID:
15136448
45.

Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2.

Meyer AM, Dwyer-Nield LD, Hurteau GJ, Keith RL, O'Leary E, You M, Bonventre JV, Nemenoff RA, Malkinson AM.

Carcinogenesis. 2004 Aug;25(8):1517-24. Epub 2004 Mar 19.

PMID:
15033900
46.
47.

Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections.

Miller YE, Dwyer-Nield LD, Keith RL, Le M, Franklin WA, Malkinson AM.

Cancer Lett. 2003 Aug 20;198(2):139-44.

PMID:
12957351
48.

Mycobacterium tuberculosis presenting as an infected pulmonary bulla.

Bull TM, Keith RL, Kraft M, Dempsy EC, Miller YE.

Int J Tuberc Lung Dis. 2003 May;7(5):504. No abstract available.

PMID:
12757057
49.

Hypoxia induces different genes in the lungs of rats compared with mice.

Hoshikawa Y, Nana-Sinkam P, Moore MD, Sotto-Santiago S, Phang T, Keith RL, Morris KG, Kondo T, Tuder RM, Voelkel NF, Geraci MW.

Physiol Genomics. 2003 Feb 6;12(3):209-19. Erratum in: Physiol Genomics. 2003 Mar 18;13(1):79.

PMID:
12464684
50.

Randomized controlled trial with low-dose spiral CT for lung cancer screening: feasibility study and preliminary results.

Garg K, Keith RL, Byers T, Kelly K, Kerzner AL, Lynch DA, Miller YE.

Radiology. 2002 Nov;225(2):506-10.

PMID:
12409588

Supplemental Content

Loading ...
Support Center